Discovery and Optimization of a Novel Brain-Penetrant Colchicine-Binding Site Ligand for Treatment of Glioma

Abstract The limited number of approved drugs for treatment of brain cancers is very apparent. Temozolomide and Vorasidenib continue to be the only approved brain-permeable, orally available drugs. A novel class of highly brain-penetrant tubulin-binding ligands was discovered through rigorous structure−activity-relationship (SAR) studies. The lead compounds were validated through tubulin polymerization assays and co-crystallization, demonstrating destabilization of microtubules by binding to the colchicine site of tubulin. The ligands maintain core interactions with tubulin like those of colchicine; however, both the tubulin βT7 and αT5 loops adopt flipped conformations compared with the colchicine-bound state. SAR studies revealed high selectivity for substitutions, with a small number of indispensable moieties, and led to the selection of small-molecule compound 40 as the clinical candidate. Compound 40 is highly potent, has high gut and moderate brain permeability, a favorable clearance and cytochrome P450 inhibition/induction profile, and demonstrated activity in models of glioma.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-10-08
DOI
https://doi.org/10.1021/acs.jmedchem.6c01659
Primary Topic
Synthesis and biological activity
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery and Optimization of a Novel Brain-Penetrant Colchicine-Binding Site Ligand for Treatment of Glioma

Michel Olivier Steinmetz, Alex G. Batrouni, Jeremy C. Smith, Mustafa Tansel Kendırlı et al.
Journal of Medicinal Chemistry
Synthesis and biological activity
article

Discovery and Optimization of a Novel Brain-Penetrant Colchicine-Binding Site Ligand for Treatment of Glioma

Michel Olivier Steinmetz, Alex G. Batrouni, Jeremy C. Smith, Mustafa Tansel Kendırlı, Dinesh Chimmanamada, Jacob P. Matson, Archna Ravi, Andrea Enrico Prota, Anne‐Catherine Abel, Maria-Dorothea Nastke, Lawrence David Recht, Micholas Dean Smith, Eric Michael Grund, Andressa L. Mota, Niven R. Narain, Pedro N. Pozo, Vivek K. Vishnudas, Stéphane Gesta
article en

Abstract

Abstract The limited number of approved drugs for treatment of brain cancers is very apparent. Temozolomide and Vorasidenib continue to be the only approved brain-permeable, orally available drugs. A novel class of highly brain-penetrant tubulin-binding ligands was discovered through rigorous structure−activity-relationship (SAR) studies. The lead compounds were validated through tubulin polymerization assays and co-crystallization, demonstrating destabilization of microtubules by binding to the colchicine site of tubulin. The ligands maintain core interactions with tubulin like those of colchicine; however, both the tubulin βT7 and αT5 loops adopt flipped conformations compared with the colchicine-bound state. SAR studies revealed high selectivity for substitutions, with a small number of indispensable moieties, and led to the selection of small-molecule compound 40 as the clinical candidate. Compound 40 is highly potent, has high gut and moderate brain permeability, a favorable clearance and cytochrome P450 inhibition/induction profile, and demonstrated activity in models of glioma.

Journal of Medicinal Chemistry
University of Miami (US), Paul Scherrer Institute (CH), University Hospital of Basel (CH), Bethesda Spital (CH), University of Tennessee at Knoxville (US), Stanford University (US)
Openalex Percentile: Top 25%
Synthesis and biological activity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.